The national centralized drug procurement (NCDP) policy, known as the "4 + 7" policy in China, has transformed pharmaceutical procurement and access by leveraging healthcare institutions' collective buying power to reduce drug prices substantially. This policy has profoundly impacted drug pricing mechanisms, healthcare expenditures, market dynamics, and the quality of available drugs. This commentary evaluates the efficacy, challenges, and broader implications of the NCDP, summarizes the current state of post-marketing monitoring of selected generic drugs for centralized procurement, and presents relevant considerations.
基金：
Beijing Hospital Authority Ascent Plan [DFL20190803]; China Association for Science and Technology Talent Tank Yong Talent Program [20220615ZZ07110070]; National Healthcare Security Administration [JCS-ZCHT-2023-002]
第一作者机构：[1]Capital Med Univ, Xuanwu Hosp, Clin Med Coll 1, Dept Pharm, 45 Changchun St, Beijing 100053, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Zhizhou,Wang Ke,Hua Yiming,et al.Impact and implications of national centralized drug procurement in China[J].INTERNATIONAL JOURNAL OF CLINICAL PHARMACY.2024,doi:10.1007/s11096-024-01767-1.
APA：
Wang, Zhizhou,Wang, Ke,Hua, Yiming,Dong, Xianzhe&Zhang, Lan.(2024).Impact and implications of national centralized drug procurement in China.INTERNATIONAL JOURNAL OF CLINICAL PHARMACY,,
MLA：
Wang, Zhizhou,et al."Impact and implications of national centralized drug procurement in China".INTERNATIONAL JOURNAL OF CLINICAL PHARMACY .(2024)
